Targeting of phospholamban by peroxynitrite decreases beta-adrenergic stimulation in cardiomyocytes

Mark J Kohr1, Honglan Wang, Debra G Wheeler

  • 1Department of Physiology and Cell Biology, Davis Heart and Lung Research Institute, The Ohio State University, 304 Hamilton Hall, 1645 Neil Avenue, Columbus, OH 43210, USA.

Cardiovascular Research
|November 17, 2007
PubMed
Abstract

Insights

Peroxynitrite impairs cardiac beta-adrenergic function by reducing phospholamban (PLB) phosphorylation, a key mechanism in heart failure. This study reveals PLB

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Pathophysiology
  • Molecular Cardiology

Background:

  • Peroxynitrite is implicated in cardiac disorders like heart failure.
  • The mechanisms underlying peroxynitrite's anti-adrenergic effects are not fully understood.
  • Phospholamban (PLB) is crucial for cardiac excitation-contraction coupling.

Purpose of the Study:

  • To investigate phospholamban's role in peroxynitrite-induced cardiac dysfunction.
  • To elucidate the mechanism by which peroxynitrite affects beta-adrenergic signaling.

Main Methods:

  • Isolated cardiomyocytes from wild-type and PLB knockout mice were used.
  • Myocyte shortening and calcium transients were measured under beta-adrenergic stimulation.
  • Peroxynitrite donor (SIN-1) and phospholamban phosphorylation were analyzed.

Main Results:

  • Peroxynitrite significantly reduced beta-adrenergic-stimulated myocyte function and Ca(2+) transients in wild-type but not PLB knockout myocytes.
  • Peroxynitrite decreased phospholamban phosphorylation at Ser16.
  • Inhibition of protein phosphatases reversed the functional effects of peroxynitrite.

Conclusions:

  • Peroxynitrite impairs cardiac beta-adrenergic responsiveness by reducing phospholamban phosphorylation via protein phosphatase activation.
  • This mechanism may contribute to beta-adrenergic dysfunction in cardiomyopathies.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...